Literature DB >> 7676810

Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients.

M Huell1, S Strauss, B Volk, M Berger, J Bauer.   

Abstract

Interleukin-6 (IL-6) immunoreactivity has previously been shown in plaques in Alzheimer's disease (AD) and elevated IL-6 concentrations have been measured biochemically in brains of AD patients. In this study, we investigated the appearance of IL-6 immunoreactivity in AD plaques according to the stage of plaque formation. Using the Bielschowsky silver-staining method, we were able to differentiate between four types of plaques described earlier: diffuse, primitive, classic and compact. While diffuse plaques represent the early stage of plaque formation, primitive and classic plaques are thought to represent later stages of plaque development. We investigated serial sections of paraffin-embedded cortices of ten clinically diagnosed and histopathologically confirmed AD patients and ten patients with no clinical history of dementia. We found plaques in the brains of both nondemented and demented persons using the silver staining method or immunohistochemistry with antibodies against the amyloid precursor protein. In the group of clinically nondemented persons, diffuse plaques were the predominant plaque type, whereas primitive plaques formed the larger portion of lesions in the group of AD brains. IL-6 could not be detected in plaques of patients without dementia. Many IL-6-positive plaques were found in six of the AD brains and to a smaller extent in the other four AD cases. In the six cases with a large number of IL-6-positive plaques, IL-6 was found in a significantly higher ratio of diffuse plaques than expected from a random distribution of IL-6 in all plaque types.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7676810     DOI: 10.1007/bf00571510

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  52 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

2.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

3.  Senile plaques do not progressively accumulate with normal aging.

Authors:  I R Mackenzie
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

4.  Cerebrospinal fluid interleukin-6 activity in HIV infection and inflammatory and noninflammatory diseases of the nervous system.

Authors:  M A Laurenzi; A Sidén; M A Persson; G Norkrans; L Hagberg; F Chiodi
Journal:  Clin Immunol Immunopathol       Date:  1990-11

5.  Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices.

Authors:  J Bauer; S Strauss; U Schreiter-Gasser; U Ganter; P Schlegel; I Witt; B Yolk; M Berger
Journal:  FEBS Lett       Date:  1991-07-08       Impact factor: 4.124

6.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.

Authors:  I L Campbell; C R Abraham; E Masliah; P Kemper; J D Inglis; M B Oldstone; L Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

7.  Ultrastructure of diffuse plaques in senile dementia of the Alzheimer type: comparison with primitive plaques.

Authors:  H Yamaguchi; Y Nakazato; M Shoji; M Takatama; S Hirai
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

8.  A special type of senile plaque, possibly an initial stage.

Authors:  A Probst; H Brunnschweiler; C Lautenschlager; J Ulrich
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

9.  Temporal sequence of plaque formation in the cerebral cortex of non-demented individuals.

Authors:  D L Sparks; H Liu; S W Scheff; C M Coyne; J C Hunsaker
Journal:  J Neuropathol Exp Neurol       Date:  1993-03       Impact factor: 3.685

10.  Interleukin-6 and selected plasma proteins in healthy persons of different ages.

Authors:  K Hager; U Machein; S Krieger; D Platt; G Seefried; J Bauer
Journal:  Neurobiol Aging       Date:  1994 Nov-Dec       Impact factor: 4.673

View more
  39 in total

1.  Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis.

Authors:  B Kaltschmidt; M Uherek; H Wellmann; B Volk; C Kaltschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 2.  The role of inflammatory processes in Alzheimer's disease.

Authors:  G Joseph Broussard; Jennifer Mytar; Rung-chi Li; Gloria J Klapstein
Journal:  Inflammopharmacology       Date:  2012-04-26       Impact factor: 4.473

Review 3.  Can consuming flavonoids restore old microglia to their youthful state?

Authors:  Saebyeol Jang; Rodney W Johnson
Journal:  Nutr Rev       Date:  2010-12       Impact factor: 7.110

4.  Do nonsteroidal anti-inflammatory drugs have a protective effect against dementia?

Authors:  F L Van Muiswinkel; P Eikelenboom
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

Review 5.  Interleukin 6 and cognitive dysfunction.

Authors:  Isabel Trapero; Omar Cauli
Journal:  Metab Brain Dis       Date:  2014-04-30       Impact factor: 3.584

6.  S100beta induction of the proinflammatory cytokine interleukin-6 in neurons.

Authors:  Y Li; S W Barger; L Liu; R E Mrak; W S Griffin
Journal:  J Neurochem       Date:  2000-01       Impact factor: 5.372

7.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

8.  Sp1 and Smad transcription factors co-operate to mediate TGF-beta-dependent activation of amyloid-beta precursor protein gene transcription.

Authors:  Fabian Docagne; Cecilia Gabriel; Nathalie Lebeurrier; Sylvain Lesné; Yannick Hommet; Laurent Plawinski; Eric T Mackenzie; Denis Vivien
Journal:  Biochem J       Date:  2004-10-15       Impact factor: 3.857

Review 9.  Macrophages in Alzheimer's disease: the blood-borne identity.

Authors:  David Gate; Kavon Rezai-Zadeh; Dominique Jodry; Altan Rentsendorj; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2010-06-02       Impact factor: 3.575

10.  Effects of immunomodulatory substances on phagocytosis of abeta(1-42) by human microglia.

Authors:  Erik Hjorth; Dan Frenkel; Howard Weiner; Marianne Schultzberg
Journal:  Int J Alzheimers Dis       Date:  2010-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.